Current Neurology and Neuroscience Reports

, Volume 6, Issue 4, pp 311–318 | Cite as

Antiepileptic therapy in patients with central nervous system malignancies

  • Glen H. J. Stevens


More than 200,000 patients are diagnosed with primary or metastatic brain tumors each year in the United States. Of these patients, 20% to 40% will develop seizures at presentation, and another 20% to 40% will require treatment for seizures during their illness. Although the use of antiepileptic drugs (AEDs) in patients who have had seizures seems reasonable, the issue of prophylactic AED use for patients who have not had a seizure is an intensely debated subject. The American Academy of Neurology released a position statement in May 2000 addressing the use of anticonvulsants in newly diagnosed brain tumor patients who have never had a seizure. After a review of the literature, including all trials showing class I evidence, multivariate analysis using calculated odds ratios failed to show a prophylactic benefit of preventing a first seizure versus the risk of side effects and recommended not using prophylactic anticonvulsants in newly diagnosed patients with brain tumor. Despite this recommendation, a recent survey of the American Association of Neurologic Surgeons revealed that most neurosurgeons still use anticonvulsants prophylactically in patients with brain tumor. This review mainly includes primary brain tumors, but most of the concepts are transferable to patients with metastatic tumors.


Brain Tumor Gabapentin Lamotrigine Topiramate Pregabalin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Primary Brain Tumors in the United States: Statistical Report. Chicago, IL: Central Brain Tumor Registry of the United States; 1997–2001.Google Scholar
  2. 2.
    Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. Cancer J Clin 1999, 49:8–31.Google Scholar
  3. 3.
    Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886–1893. Required reading for anyone prescribing anticonvulsants.PubMedGoogle Scholar
  4. 4.
    Sirven JI, Wingerchuk DM, Drazkowski JF, et al.: Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489–1494.PubMedGoogle Scholar
  5. 5.
    Sirven JI: Classifying seizures and epilepsy: a synopsis. Semin Neurol 2002, 22:237–246. Excellent review of seizure classification.PubMedCrossRefGoogle Scholar
  6. 6.
    French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401–409.PubMedCrossRefGoogle Scholar
  7. 7.
    French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs, II: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401–409. Provides practice parameters to help guide decision making in treatment.PubMedCrossRefGoogle Scholar
  8. 8.
    Kessler RC, Bavis RB, Foster DF, et al.: Long-term trends in the use of complimentary and alternative medical therapies in the United States. Ann Intern Med 2001, 135:262–268.PubMedGoogle Scholar
  9. 9.
    Eisenbery DM, Davis RB, Ettner SL, et al.: Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998, 280:1569–1575.CrossRefGoogle Scholar
  10. 10.
    Hariharan S, Landol. J, More J, et al.: Alternative therapy use by malignant glioma patients: data from the glioma outcomes project. Neuro-oncol 2000, 2:268.Google Scholar
  11. 11.
    Chang SM, Parney IF, Haung MS, et al.: Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557–564. This is an excellent up-to-date analysis of practice patterns for newly diagnosed high-grade gliomas from a multi-institutional study.PubMedCrossRefGoogle Scholar
  12. 12.
    Verhoef MJ, Hagan N, Pelletier G, Forsyth P: Alternative therapy use in neurologic diseases: use in brain tumor patients. Neurology 1999, 52:617–622.PubMedGoogle Scholar
  13. 13.
    Plunkett M, Klein E, Alldredge B: Use of complimentary and alternative medicine products by patients with epilepsy. How common is it? Epilepsia 2004, 45(Suppl 7):149.Google Scholar
  14. 14.
    Khoi DT, Kossoff EH, Rubenstrein JE, et al.: Can you predict immediate, complete, and sustained response to the ketogenic diet? Epilepsia 2005, 46:580–582.CrossRefGoogle Scholar
  15. 15.
    Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995, 14:202–208.PubMedGoogle Scholar
  16. 16.
    Cole AJ: Initial individualized selection of long-term anticonvulsants drugs by neurologists. Neurology 2004, 63(Suppl 4):S1-S2.PubMedGoogle Scholar
  17. 17.
    Vecht CJ, Wagner GL, Wilms EB: Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003, 30(Suppl 19):49–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Perry JR, Sawaka C: Add-on gabapentin for refractory seizures in patients with brain tumors. Can J Neurol Sci 1996, 23:128–131.PubMedGoogle Scholar
  19. 19.
    Newton HB, Goldlust S, Pearl D: Retrospective analysis of levetiracetam for the treatment of seizures in brain tumor patients. Neurology 2005, 64(Suppl 1):A47.Google Scholar
  20. 20.
    Larson SE, Sirven JI, Drazkowski JF, Zimmerman RS: Efficacy and tolerability of levetiracetam in patients with brain tumors and seizures. Epilepsia 2004, 45(Suppl 7):124.Google Scholar
  21. 21.
    Penovch PE, Dickens DL, Gates JR, et al.: Treating seizures due to brain neoplasms: rational new choices. Epilepsia 2004, 45(Suppl 7):311.Google Scholar
  22. 22.
    Wagner GL, Wilms EB, Van Donselaar CA, Vecht CHJ: Levetiracitam: preliminary experience in patients with primary brain tumors. Seizure 2003, 12:585–586.PubMedCrossRefGoogle Scholar
  23. 23.
    Stevens GH, Vogelbaum MA, Suh JH, et al.: Levetiracetam use in brain tumor patients. Neurology 2005, 64(Suppl 1):A48.Google Scholar
  24. 24.
    Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992, 22:1–21.PubMedGoogle Scholar
  25. 25.
    Nelson DR, Koymans L, Kamataki T, et al.: P450 super family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical trial and pharmacokinetics study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940–2949.PubMedGoogle Scholar
  27. 27.
    Fetell MR, Grossman SA, Fischer JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997, 15:3121–3128.PubMedGoogle Scholar
  28. 28.
    Bourg V, Lebrun C, Chichmahian RM, et al.: Nitrosoureacisplatinum based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001, 12:217–219.PubMedCrossRefGoogle Scholar
  29. 29.
    Bittigua P, Sifringer M, Genz K, et al.: Antineoplastic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 2002, 99:15089–15094.CrossRefGoogle Scholar
  30. 30.
    Jaeckle K, Ballman K, Uhm J, et al.: Relationship of administration of enzyme-inducing anticonvulsants (EIAC) to survival in patients with glioblastoma: a North Central Cancer treatment Group (NCCTG) study. Neuro-oncol 2004, 6:376.Google Scholar
  31. 31.
    Chalifoux R, Elisevich K: Effect on ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 1996, 97:169–182.Google Scholar
  32. 32.
    Rogers L, Morris H, Lupica K: Effect of cranial irradiation on seizure frequency in adults with low grade astrocytomas and medically intractable epilepsy. Neurology 1993, 43:1599–1601.PubMedGoogle Scholar
  33. 33.
    Hwang SL, Lin CL, Lee KS, et al.: Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wein) 2004, 146:589–594.CrossRefGoogle Scholar
  34. 34.
    Regis J, Bartolomei F, Rey M, et al.: Gamma knife surgery for mesial temporal lobe epilepsy. J Neurosurg 2000, 93(Suppl 3):141–146.PubMedGoogle Scholar
  35. 35.
    Regis J, Rey M, Bartolomei F, et al.: Gamma knife surgery in mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia 2004, 45:504–515.PubMedCrossRefGoogle Scholar
  36. 36.
    Wyllie ER, Luders H, Morris HH III, et al.: Clinical outcome after complete or partial resection for intractable epilepsy. Neurology 1987, 37:1634–1641.PubMedGoogle Scholar
  37. 37.
    Berger MS, Ghatan S, Haglund MM, et al.: Low grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993, 79:62–69.PubMedGoogle Scholar
  38. 38.
    Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opin Oncol 2002, 14:299–307.PubMedCrossRefGoogle Scholar
  39. 39.
    Jooma R, Yeh HS, Privitera MD, Gartner M: Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. J Neurosurg 1995, 83:231–236.PubMedCrossRefGoogle Scholar
  40. 40.
    Labar D, Murphy J, Tecoma E: Vagus nerve stimulation for medication-resistant generalized epilepsy. EO4 Study Group Neurology 1999, 52:1510–1512.Google Scholar
  41. 41.
    Karceski S: Devices in the treatment of epilepsy. Semin Neurol 2002, 22:259–268.PubMedCrossRefGoogle Scholar
  42. 42.
    Ng M, Devinsky O: Vagus nerve stimulation for refractory idiopathic generalized epilepsy. Seizure 2004, 13:176–178.PubMedCrossRefGoogle Scholar
  43. 43.
    Wilder BJ: Vagal nerve stimulation. In Epilepsia: A Comprehensive Textbook. Edited by Engle JJr, Pedley TA. Philadelphia: Lippincott-Raven; 1997:1353–1358.Google Scholar
  44. 44.
    Fischer RS, Mirski M, Krauss G: Brain stimulation. In Epilepsy: A Comprehensive Textbook. Edited by Engle JJr, Pedley TA Philadelphia: Lippincott-Raven; 1997:1867–1875.Google Scholar
  45. 45.
    Fischer RS, Uematsu S, Kraus GL, et al.: Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures. Epilepsia 1992, 33:841–851.CrossRefGoogle Scholar
  46. 46.
    Bergey GK, Britton JW, Cuscino GD, et al.: Implementation of an external responsive neurostimulator in patients with intractable epilepsy undergoing intracranial seizure monitoring. Epilepsia 2002, 43(Suppl 7):191.Google Scholar
  47. 47.
    Kubota F, Kifune A, Shibata N, et al.: Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res 1999, 33:93–97.PubMedCrossRefGoogle Scholar
  48. 48.
    Hahn TJ, Birge SJ, Scara CR, et al.: Phenobarbital induced alterations in vit D metabolism. J Clin Invest 1972, 51:741–748.PubMedCrossRefGoogle Scholar
  49. 49.
    Ensrund WE, Walczak TS, Blackwell T: Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004, 62:2051–2057.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Cleveland Clinic FoundationBrain Tumor Institute, Taussig Cancer Center-R20ClevelandUSA

Personalised recommendations